Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Lantern Pharma (LTRN) Stock Price & Analysis
216 Followers
LTRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.38 - $11.99
Previous Close$4.38
Volume17.72K
Average Volume (3M)116.40K
Market Cap
$47.12M
Enterprise Value$6.06M
Total Cash (Recent Filing)$41.30M
Total Debt (Recent Filing)$234.47K
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Aug 06, 2024EPS Estimate
-$0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding10,758,805
10 Day Avg. Volume97,273
30 Day Avg. Volume116,398
Standard Deviation0.21
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.09
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Lantern Pharma News
PremiumCompany Announcements
Lantern Pharma Announces Fiscal Year and Q4 Results WebinarBulls Say, Bears Say
Bulls Say
Potential SynergyThere is potential for combining LP-184 with existing approved therapies, which could result in synergistic effects.
Safety And ToleranceThe company has administered escalating doses of LP-184 to five cohorts of patients without observing any dose-limiting toxicities.
Study ExpansionEnrollment for the Harmonic Phase 2 study is progressing in the US and Asia.
Bears Say
Study ChallengesSome KOLs have also noted challenges with using platinum alone as a placebo arm.
Study EnrollmentEnrollment in the Harmonic study has been quite slow given the first patient was enrolled over a year ago.
Supply IssuesThere is a shortage of platinum chemotherapy which has impacted enrollment of clinical trials.
---
Ownership Overview
24.55% Insiders
4.32% Mutual Funds
5.81% Other Institutional Investors
65.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $2.38 and its highest was $11.99 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Currently, no data Available
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 06, 2024 which is in 30 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on May 09, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.43 by -$0.08.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Overvalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -$0.55.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 10,758,805 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.43. Following the earnings report the stock price went down -9.545%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Among the largest hedge funds holding Lantern Pharma, Inc.’s share is Carlson Capital LP. It holds Lantern Pharma, Inc.’s shares valued at N/A.
---
Lantern Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
LTRN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 60.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $378.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 9.8%
Last 30 Days ▼ 9.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.92%
12-Months-Change
Fundamentals
Return on Equity
-39.70%
Trailing 12-Months
Asset Growth
-28.42%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves three small molecule drug candidates namely LP-100, LP-184, and LP-300.
---
LTRN Company Deck
---
LTRN Earnings Call
Q1 2024
0:00 / 0:00
---
LTRN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---